Nachrichten zur BioCryst Pharmaceuticals Inc. Aktie

BioCryst posts long-term data for hereditary angioedema therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why BioCryst Pharmaceuticals Stock Slid Today

The biotechs immediate future doesnt look profitable....…

BioCryst Pharmaceuticals (BCRX) Q4 2021 Earnings Call Transcript

BCRX earnings call for the period ending December 31, 2021....…

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2021 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst slips after lower-than-expected Q4 2021 results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Recap: BioCryst Pharmaceuticals Q4 Earnings

  BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Heres what investors need to…

BioCryst Pharmaceuticals Q4 2021 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Aufsichtsrat verkauft Aktien von BioCryst Pharmaceuticals im Wert von 92.500$

Abercrombie, George B. - Aufsichtsrat - Tag der Transaktion: 2022-02-15...…

Form 8-K BIOCRYST PHARMACEUTICALS For: Feb 04

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Appoints Machelle Sanders to Board of Directors

RESEARCH TRIANGLE PARK, N.C., Feb. 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the…

BioCryst Pharmaceuticals: Updates To Thesis, Clinical And Commercial Momentum Accelerating

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

Why BioCryst Pharmaceuticals Stock Is Skyrocketing This Week

Investors loved the drugmakers update earlier this week....…

BioCryst Pharmaceuticals (BCRX) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Is On Fire: What Do Options Traders Expect Next?

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) surged 11.16% to close Tuesdays trading at $16.43, after the company announced upbeat…

Options Action: Pharma on fire

Optimize Advisors' Mike Khouw looks at interesting options activity in BioCryst Pharma as traders get bullish following a huge revenue…

BioCryst (BCRX) Moves 27.9% Higher: Will This Strength Last?

BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…

BioCryst (BCRX) Stock Up on Q4 Orladeyo Preliminary Sales

BioCrysts (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance…

Thinking about buying stock in Splash Beverage, TSR Inc, Phio Pharmaceuticals, Pacific Biosciences of California, or BioCryst Pharmaceuticals?

NEW YORK, Jan. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SBEV, TSRI, PHIO, PACB, and BCRX. To…

Why BioCryst Pharmaceuticals Stock Is Jumping on Monday

Investors are cheering for preliminary fourth-quarter Orladeyo sales and guidance for 2022....…

Thinking about buying stock in Tilray, Avinger, Reliance Global, BioCryst Pharmaceuticals, or Codex DNA?

NEW YORK, Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TLRY, AVGR, RELI, BCRX, and DNAY. To…

BioCryst sees Q4 Orladeyo revenue of $45.6M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K BIOCRYST PHARMACEUTICALS For: Jan 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst begins patient enrollment in REDEEM-1 trial of BCX9930 for rare blood disorder

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K BIOCRYST PHARMACEUTICALS For: Jan 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the…

BioCryst Provides Tremendous Option Value

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

3 unglaublich günstige Wachstumsaktien, die einen zum Millionär machen können

Bionano Genomics, BioCryst Pharmaceuticals und NRx Pharmaceuticals haben alle das Potenzial, ihre frühen Aktionäre reich zu machen. Der Artikel 3 unglaublich…

BioCryst announces inducement grants to 11 new employees

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930

BioCryst (BCRX) starts patient enrollment in the pivotal REDEEM-2 study evaluating BCX9930 for treating patients with paroxysmal nocturnal hemoglobinuria....…

3 Incredibly Cheap Growth Stocks That Could Make You a Millionaire

Bionano Genomics, BioCryst Pharmaceuticals, and NRx Pharmaceuticals all have the potential to make their early shareholders rich....…

BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the…

Form 8-K BIOCRYST PHARMACEUTICALS For: Nov 29

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Pharmaceuticals higher following two insider buys

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo

Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth read more...…

Thinking about buying stock in Innoviz Technologies, Avaya Holdings, BioCryst Pharmaceuticals, Lithium Americas Corp, or Innoviz Technologies?

NEW YORK, Nov. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INVZ, AVYA, BCRX, LAC, and INVZ. To…

Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and Orladeyo from BioCryst

Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and Orladeyo from BioCryst...…

Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX),…

BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets

—Provides funding for BCX9930/oral Factor D program across multiple indications—...…

Insiderhandel: Aufsichtsrat verkauft Aktien von BioCryst Pharmaceuticals im Wert von 61.350$

Abercrombie, George B. - Aufsichtsrat - Tag der Transaktion: 2021-11-15...…

BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)

Data from APeX-S showed patients had more than 80 percent attack free months after switching to ORLADEYO from injectable prophylactic…

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2021 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Pharmaceuticals (BCRX) Q3 2021 Earnings Call Transcript

BCRX earnings call for the period ending September 30, 2021....…

BioCryst Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -10.00% and 8.59%, respectively, for the quarter ended September 2021. Do the…

Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for

BioCryst (BCRX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…